A genetically engineered vaccine against Escherichiacoli O157 tested in a small group of adult volunteers appears safe and stimulates the production of antibodies against the potentially fatal pathogen, researchers reported in the February issue of the Journal of Infectious Diseases.
A vaccine against E coli O157 would be a valuable weapon against the pathogen, because the infection doesn't respond well to antibiotics. Moreover, some researchers believe that antibiotics may increase the incidence of a sometimes fatal complication of the infection, hemolytic uremic syndrome, by promoting the release of a bacterial toxin into the bloodstream.
Stephenson J. E coli O157 Vaccine. JAMA. 1998;279(11):818. doi:10.1001/jama.279.11.818
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: